In fact, immune checkpoint inhibitors (ICIs), especially anti-PD-1 and anti-PD-L1 blockers, have changed the traditional treatment mode and achieved unprecedented long-lasting responses in patients with melanoma. Here, CD274 is linked to melanoma.